NPPA Updated Retail Price Notification 28 November 2025 | Drug Prices Under DPCO 2013

NPPA Updated Retail Price Notification 28 November 2025 | Drug Prices Under DPCO 2013

In a significant move to ensure affordable healthcare, the National Pharmaceutical Pricing Authority (NPPA) has issued S.O. 5476(E) on November 28, 2025, fixing the retail prices of several critical drug formulations. This latest NPPA drug price notification 2025 covers a range of essential medicines from cardiovascular, anti-infective, respiratory, and diabetic categories. For patients, healthcare providers, and pharmacists across India, this NPPA latest drug prices update brings much-needed transparency and regulatory clarity.

Below, we break down the key formulations, their approved retail price in India, and what this means for access to essential treatment.

Overview of the NPPA Retail Price List 2025

The NPPA new price list includes 11 formulations, each with a fixed maximum retail price (MRP) exclusive of GST. The authority exercised its powers under the Drugs (Prices Control) Order (DPCO) 2013 to ensure these government drug prices remain patient-friendly while allowing manufacturers a reasonable margin.

This NPPA notification 2025 is especially important for new drugs under Paragraph 2(1)(u) of the DPCO. Manufacturers must now align their pricing with the gazette and comply with post-notification requirements such as issuing price lists in Form V.

 Important Compliance Notes from the NPPA Order

• GST Clause: The retail price is exclusive of GST. Manufacturers may add GST only if paid or payable to the government.
• Price List Submission: Manufacturers must submit a price list in Form V to NPPA via IPDMS and to State Drug Controllers.
• Display Requirement: Retailers and dealers must display the price list prominently at their premises.
• Previous Orders Superseded: All earlier price orders for these formulations stand superseded.

Non-compliance can lead to penalties under the DPCO 2013 and the Essential Commodities Act, 1955.

Why This Notification Matters

The NPPA retail price notification 2025 reinforces the government’s commitment to pharmaceutical price regulation in India. By capping prices of essential medicines, the NPPA ensures that life-saving treatments remain within reach of the common man.

For the pharmaceutical industry, it brings clarity and a level playing field. For patients, it means predictable healthcare expenses. And for doctors, it ensures prescribed medicines are affordable and available.

For the complete CDSCO guidance document, please click here to view the official file.

Note:
Cases related to Pharmaceuticals are highly technical and knowledge-driven. If you're searching for a drugs and cosmetics lawyer in India, a pharmaceutical lawyer, Mace Corporate Associates is the perfect place. If you are searching for a DPCO Lawyer for overcharging cases or DPCO Compliance, Mace can assist you well. May it be a clinical trial Lawyer or a Medical device lawyer, Mace can be of great and perfect match for Pharmaceutical litigation. Mace has an accomplished track record for Not of Standard Quality Cases, Licensing Cases etc.